Executive Summary

OneSource Specialty Pharma reported Q1 FY27 revenue of ₹449 Cr (+37% YoY) and EBITDA of ₹123.3 Cr (27.5% margin), driven by the launch of generic GLP-1 (Semaglutide) in India and Canada. Management reiterated its target of achieving $400M (~₹3,320 Cr) in revenue at a 40% EBITDA margin by FY28, backed by a $100M capex program. However, because Q1 FY27 figures were already released on July 24, 2026, this announcement is mostly old news (already_priced_in: true). Crucially, the promoter holding stands at 30.48% (below the 35% threshold) with a 70% pledge level. Per strict governance rules, the multibagger verdict is capped at POSSIBLE with a confidence score of 0.45.

1. Industry Context & Capital Intensity

• Industry: CDMO / Complex Injectables & Biologics.
• Capital Intensity: HIGH. Complex sterile injectables and biologics facilities require $100M+ initial capex and long gestation periods (~2 years for line qualification and validation).
• Execution Difficulty: High. Regulated markets require stringent USFDA clearances; 50% of revenue comes from the US. Any warning letter or regulatory delay can impact up to half of revenues.
• Industry CAGR: Estimated at 12.0% globally for specialty CDMOs.

2. Ramp-Aware Execution & Financial Assessment

• TTM Base: TTM Revenue of ₹1,422 Cr, TTM PAT of -₹49 Cr, and ROCE of 2.0% reflect a business emerging from heavy restructuring.
• Year 1 Ramp: Q1 FY27 revenue of ₹449 Cr yields an annualized run-rate of ~₹1,800 Cr, representing a 26.6% uplift over FY26 revenue (₹1,421.56 Cr).
• Steady-State Target (FY28): Target revenue of $400M (~₹3,320 Cr at ₹83/$) implies a 133.5% uplift over TTM. Assuming a 40% EBITDA margin (₹1,328 Cr) and accounting for ~₹350 Cr in interest/depreciation, steady-state PAT could reach ~₹650-700 Cr (EPS ~₹85-90). Baseline EPS is currently negative (-₹6.44), so direct percentage uplift is not computable (null).

3. Quality & Governance Risk Caps

• Promoter Holding Rule: Promoter equity sits at 30.48%, failing the 35% threshold cap rule.
• Pledge & Related Party Issues: Promoter pledge is ~70%, and the firm relies on ₹450 Cr of corporate guarantees from Strides.
• Management Resignation: The Global Head of Injectables resigned on July 24, 2026.
• Verdict Cap: Governance caps require a maximum rating of POSSIBLE and confidence <= 0.5.

4. Valuation & Scenario Calibration

• Base Case (35% Upside over 24-36m): Successful execution of GLP-1 expansion and second cartridge line deployment. FY28 revenue reaches ~$330-350M with EBITDA margins around 32-35%.
• Bull Case (85% Upside over 24-36m): Reaching full $400M guidance with 40% EBITDA margins and successful US launch of semaglutide without regulatory glitches.
• Bear Case (-40% Downside): USFDA inspection observations at key sterile facilities or pledge-related equity distress dragging down multiples.

OneSource Specialty Pharma (ONESOURCE) - Equity Research Report

Analysis Date: 2026-07-24
Current Price: ₹1,653.9 | Market Cap: ₹12,657 Cr | Trailing P/E: N/A (Turnaround) | P/B: 2.1x

1. Catalyst Evaluation & Ramp-Aware Impact Math

OneSource Specialty Pharma reported its Q1 FY27 financial and operational results on July 24, 2026: * Q1 FY27 Revenue: ₹449 Cr (+37% YoY from ₹327 Cr in Q1 FY26). * EBITDA & Margins: ₹123.3 Cr with EBITDA margin reaching 27.5% (+600 bps QoQ improvement). * Drivers: Launch of generic Semaglutide (GLP-1) in Canada and India. * Operational Milestone: Doubling of sterile production days via Q2 commercialization of its second cartridge line; 80% of $100M capex committed. * Guidance Reaffirmed: FY28 organic revenue guidance of $400M (~₹3,780 Cr) at 40% EBITDA margin.

Financial Ramp Math: * TTM Revenue: ₹1,422 Cr. * Year-1 Run Rate (FY27): Q1 FY27 annualized run rate = ₹449 Cr x 4 = ₹1,796 Cr (~26.3% uplift over TTM). * Steady-State Target (FY28): ₹3,780 Cr revenue (~165.8% uplift over TTM). * Margin & Earnings Expansion:
At $400M revenue (₹3,780 Cr) and 40% EBITDA margin, annual EBITDA would reach ₹1,512 Cr. Subtracting ~₹350 Cr in annual depreciation and ~₹150 Cr in interest costs leaves PBT of ~₹1,012 Cr. At a standard 25% tax rate, Net Profit (PAT) would equal ~₹759 Cr, yielding an EPS of ~₹99 per share.

2. Industry Context, Capital Intensity & Quality Gate

• Capital Intensity: HIGH. Building USFDA-compliant sterile injectable and biologics capacity requires long lead times (2+ years) and high capex ($100M program).
• Execution Difficulty: HIGH. CDMO execution in complex injectables and GLP-1 biosimilars faces regulatory audits, batch qualification hurdles, and client audit timelines.
• Industry Growth: Global CDMO sector is growing at ~12% CAGR, with high demand for GLP-1 and sterile fill-finish capabilities.
• Quality Gate Assessment: FAILED. Trailing ROCE stands at a low 2.0% due to historical restructuring losses and recent capacity ramp-up. D/E ratio is modest at 0.25, but debt is significant at ₹1,504 Cr.

3. Governance Caps & Binding Constraints

• Binding Cap Rule Applied: Promoter equity holding is 30.48% (below the 35% safety threshold). Furthermore, promoter pledge is extremely high at ~70%.
• Management Resignation: Global Head of Injectables resigned on July 24, 2026.
• Constraint Effect: Per hard risk rules, any stock with promoter holding below 35% or high promoter pledge MUST have its verdict capped at POSSIBLE (or lower) and confidence capped at <= 0.50.

4. Valuation & Scenario Calibrations

• Bull Case (₹3,060 / +85% Upside): Smooth commercial ramp of Semaglutide across non-Canadian markets, successful Q2 cartridge line deployment, guidance of $400M achieved in FY28 with EPS reaching ~₹99, leading to re-rating to 31x P/E.
• Base Case (₹2,233 / +35% Upside): Partial delay in client qualification; FY28 revenue reaches ~$320M with EBITDA margins of 32%. Annual PAT settles around ₹450 Cr (EPS ~₹58.8), trading at 38x P/E.
• Bear Case (₹1,158 / -30% Downside): Regulatory friction at USFDA facilities, high debt servicing burdens, or promoter share pledge sell-offs during market corrections, compressing valuation to book value / depressed multiples.

5. Final Verdict Rationale

While OneSource demonstrates strong operational traction in high-value CDMO areas (GLP-1 launch, cartridge line expansion, 4x RFP growth), severe governance risks—namely promoter holding at 30.48%, high promoter share pledge (~70%), and key management turnover—impose strict caps on conviction. The multibagger verdict is strictly capped at POSSIBLE with confidence set to 0.45.

DETAILED ANALYST REPORT

1. Ramp-Aware Impact Math

OneSource Specialty Pharma (ONESOURCE) has entered into a strategic manufacturing partnership with Formycon AG. While no immediate deal value is disclosed, we can model the impact based on capacity utilization of their Bangalore biologics facility.

• Current TTM Revenue: ₹1,422 Cr
• Current TTM PAT: -₹49 Cr (TTM EPS: -₹6.44)
• Bangalore Facility Capacity: The facility is USFDA and EMA approved. Currently, the company has been operating at low utilization due to gestation periods.
• Year-1 Revenue Uplift (Realistic): We assume a slow ramp-up in FY27 as tech transfer and batch validations for biosimilars take 9-12 months. Year-1 revenue uplift is estimated at 5% (approx. ₹71 Cr).
• Steady-State Revenue Uplift (Year 3): Once commercial manufacturing for Formycon's marketed and pipeline biosimilars (like FYB206 and FYB208) is fully commercialized, we estimate a 25% steady-state revenue uplift (approx. ₹355 Cr per annum).
• Margin & EPS Impact: Operating at higher capacity utilization will trigger operating leverage. Assuming a 22% OPM on the incremental ₹355 Cr revenue, incremental EBITDA would be ~₹78 Cr. At a steady-state 10% net margin on incremental revenue, incremental PAT would be ₹35.5 Cr. This would turn the company structurally profitable, delivering an estimated EPS of ~₹3.50 to ₹4.00 from this partnership alone, representing a >120% turnaround from current negative TTM EPS.

2. Industry Capital Intensity & Expected CAGR

• Capital Intensity: HIGH. Sterile injectables and biologics CDMO require massive upfront capex, stringent USFDA/EMA compliance, and long gestation periods (typically 2 years for capacity additions).
• Execution Difficulty: HIGH. Tech transfer for complex biologics and biosimilars has zero room for error. Any regulatory non-compliance or USFDA warning letter can halt 50% of revenues.
• Expected Industry CAGR: 12% structural growth driven by global pharma outsourcing and the patent cliff of major biologics.

3. Multibagger Quality Assessment

• Financials: The company is in a classic turnaround phase. Revenue has grown from ₹73 Cr in Mar 2024 to ₹428 Cr in Mar 2026. However, historical net losses have been severe (-₹391 Cr in FY24). ROCE is currently abysmal at 2.0% due to unutilized assets and high debt (₹1,504 Cr).
• Promoter & Governance: Promoter holding is low at 30.5%, and 70% of this holding is pledged. This is a major structural risk that caps our verdict and confidence.
• Catalyst Credibility: High. Formycon is a highly reputable global player, validating OneSource's technical capability.

4. Scenario Analysis (24-36 Months)

• Bull Case (Upside 110%): Successful restructuring of Strides/Steriscience/OneSource, debt reduction, USFDA clearance of all facilities, rapid tech transfer of Formycon pipeline, and EPS reaching ₹12+. Target Price: ₹3,500.
• Base Case (Upside 45%): Moderate ramp-up of Formycon products, debt levels stabilized, EPS turns positive to ₹5. Target Price: ₹2,425.
• Bear Case (Downside 30%): Regulatory issues at Bangalore facility, delayed restructuring, high interest costs leading to equity dilution or pledge invocation. Target Price: ₹1,170.

5. Verdict Rationale

The partnership is highly prestigious and structurally validates the business model. However, the combination of low promoter holding (30.5%), high promoter pledge (70%), and high debt (₹1,504 Cr) prevents a 'STRONG_CANDIDATE' rating. The stock is a 'POSSIBLE' multibagger turnaround play, contingent on execution and successful corporate restructuring.